Mizuho Forecasts Strong Price Appreciation for LivaNova (NASDAQ:LIVN) Stock

LivaNova (NASDAQ:LIVN) had its target price lifted by equities research analysts at Mizuho from $65.00 to $70.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Mizuho’s price objective would suggest a potential upside of 26.45% from the company’s current price.

Several other research analysts have also recently issued reports on the company. Robert W. Baird raised their price objective on LivaNova from $61.00 to $63.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LivaNova in a report on Wednesday, October 8th. The Goldman Sachs Group set a $55.00 price objective on LivaNova and gave the company a “neutral” rating in a research report on Wednesday, October 1st. Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 9th. Finally, Needham & Company LLC restated a “buy” rating and set a $64.00 price objective on shares of LivaNova in a research report on Wednesday, September 3rd. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, LivaNova presently has an average rating of “Moderate Buy” and an average price target of $62.43.

LivaNova Stock Up 0.3%

NASDAQ:LIVN opened at $55.36 on Thursday. The company’s 50-day simple moving average is $53.71 and its 200-day simple moving average is $48.85. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29. LivaNova has a fifty-two week low of $32.48 and a fifty-two week high of $58.91. The stock has a market capitalization of $3.02 billion, a P/E ratio of -14.23 and a beta of 1.00.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $1.11 EPS for the quarter, beating the consensus estimate of $0.91 by $0.20. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The firm had revenue of $357.80 million during the quarter, compared to analyst estimates of $342.32 million. During the same quarter in the prior year, the business posted $0.90 EPS. The business’s revenue for the quarter was up 12.5% compared to the same quarter last year. LivaNova has set its FY 2025 guidance at 3.800-3.90 EPS. On average, equities analysts anticipate that LivaNova will post 2.85 earnings per share for the current fiscal year.

Institutional Investors Weigh In On LivaNova

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Primecap Management Co. CA grew its stake in shares of LivaNova by 0.7% in the 2nd quarter. Primecap Management Co. CA now owns 4,641,352 shares of the company’s stock valued at $208,954,000 after buying an additional 32,942 shares during the period. Vanguard Group Inc. raised its position in LivaNova by 13.5% in the first quarter. Vanguard Group Inc. now owns 2,666,880 shares of the company’s stock valued at $104,755,000 after purchasing an additional 316,993 shares during the period. Artisan Partners Limited Partnership lifted its stake in shares of LivaNova by 94.5% in the 3rd quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock valued at $127,129,000 after purchasing an additional 1,179,436 shares during the last quarter. Wellington Management Group LLP increased its position in shares of LivaNova by 83.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock worth $122,858,000 after purchasing an additional 1,067,349 shares during the last quarter. Finally, AQR Capital Management LLC raised its holdings in LivaNova by 30.5% in the 2nd quarter. AQR Capital Management LLC now owns 2,049,820 shares of the company’s stock valued at $92,201,000 after buying an additional 478,525 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.